-
公开(公告)号：US20170107202A1
公开(公告)日：2017-04-20
申请号：US15290167
申请日：2016-10-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： KAP-SUN YEUNG , Timothy P. Connolly , David B. Frennesson , Katharine A. Grant-Young , Piyasena Hewawasam , David R. Langley , Zhaoxing Meng , Eric Mull , Kyle E. Parcella , Mark George Saulnier , Li-Qiang Sun , Alan Xiangdong Wang , Ningning Xu , Juliang Zhu , Paul Michael Scola
IPC: C07D401/14 , A61K31/5377 , C07D213/85 , A61K31/4439 , C07D401/12 , A61K31/4545 , A61K31/44 , C07D471/04 , C07D405/14 , A61K31/454 , C07D403/12 , A61K31/4025 , A61K31/496 , C07D205/04 , A61K31/397 , A61K31/4427 , A61K31/4453 , C07D211/22 , A61K31/40 , C07D207/14 , C07D207/12 , A61K31/138 , C07C215/20 , C07D413/14 , C07D213/82 , C07D491/08 , C07D417/14 , A61K31/541 , C07D471/08 , C07D405/12 , A61K31/135 , C07D213/80 , C07D207/16 , C07D265/30 , A61K31/5375 , A61K31/166 , C07C235/46 , C07D417/12 , A61K45/06
Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US20150025240A1
公开(公告)日：2015-01-22
申请号：US14249638
申请日：2014-04-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Yasutsugu Ueda , Timothy P. Connolly , John F. Kadow , Nicholas A. Meanwell , Tao Wang , Chung-Pin H. Chen , Kap-Sun Yeung , Zhongxing Zhang , David Kenneth Leahy , Shawn K. Pack , Nachimuthu Soundararajan , Pierre Sirard , Kathia Levesque , Dominique Thoraval
IPC: C07F9/06 , C07F9/6561
CPC classification number: A61K31/675 , A61K31/497 , A61K31/519 , A61K45/06 , C07C215/10 , C07D471/04 , C07F9/062 , C07F9/5728 , C07F9/65515 , C07F9/65586 , C07F9/6561
Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
-
公开(公告)号：US08906929B2
公开(公告)日：2014-12-09
申请号：US13959268
申请日：2013-08-05
Applicant: Bristol-Myers Squibb Company
Inventor： B. Narasimhulu Naidu , Manoj Patel , Stanley D'Andrea , Zhizhen Barbara Zheng , Timothy P. Connolly , David R. Langley , Kevin Peese , Zhongyu Wang , Michael A. Walker , John F. Kadow
IPC: C07D471/04 , C07D471/22 , C07D487/04 , A61K31/535 , A01N37/18 , A61K38/00 , A61P31/18 , C07D267/22 , C07D491/22 , A61K31/5383 , A61K31/519 , C07D498/16 , C07D487/16 , A61K45/06 , C07D498/22
CPC classification number: A61K31/5383 , A61K31/519 , A61K45/06 , C07D487/16 , C07D491/22 , C07D498/16 , C07D498/22
Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
-
4.发明授权公开(公告)号：US08871771B2
公开(公告)日：2014-10-28
申请号：US13861804
申请日：2013-04-12
Applicant: Bristol-Myers Squibb Company
Inventor： Yasutsugu Ueda , Timothy P. Connolly , John F. Kadow , Nicholas A. Meanwell , Tao Wang , Chung-Pin H. Chen , Kap-Sun Yeung , Zhongxing Zhang , David Kenneth Leahy , Shawn K. Pack , Nachimuthu Soundararajan , Pierre Sirard , Kathia Levesque , Dominique Thoraval
IPC: A61K31/497 , C07D401/00
CPC classification number: A61K31/675 , A61K31/497 , A61K45/06 , C07D471/04 , C07F9/062 , C07F9/5728 , C07F9/65515 , C07F9/65586 , C07F9/6561
Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
Abstract translation: 本发明提供前药化合物I，其药物组合物及其在治疗HIV感染中的用途。 其中：X为C或N，条件是当X为N时，R1不存在; W为C或N，条件是当W为N时，R2不存在; V是C; E是氢或其药学上可接受的盐; 并且Y选自本发明另外，本发明提供了可用于制备前药化合物I的中间体化合物II。其中：L和M独立地选自C 1 -C 6烷基，苯基，苄基，三烷基甲硅烷基， 2,2,2-三氯乙氧基和2-三甲基甲硅烷基乙氧基。
-
公开(公告)号：US09850225B2
公开(公告)日：2017-12-26
申请号：US14681772
申请日：2015-04-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Louis S. Chupak , Min Ding , Scott W. Martin , Xiaofan Zheng , Piyasena Hewawasam , Timothy P. Connolly , Ningning Xu , Kap-Sun Yeung , Juliang Zhu , David R. Langley , Paul Michael Scola
IPC: C07D319/18 , A61K31/357 , C07D405/12 , A61K31/453 , C07D405/14 , A61K31/4545 , C07D217/16 , A61K31/472 , C07D413/12 , A61K31/5377 , C07D417/12 , A61K31/541 , A61K31/496 , A61K45/06 , C07C255/54 , C07D215/14 , C07D215/18 , C07D231/56 , C07D405/04 , C07D239/26 , C07D261/08 , C07D271/06 , C07D207/26 , C07D207/335 , C07D213/30 , C07C271/28 , C07C317/22 , C07C233/36 , C07C235/42 , C07C255/13 , A61K31/165 , A61K31/277 , A61K31/40 , A61K31/4015 , A61K31/416 , A61K31/4178 , A61K31/4245 , A61K31/427 , A61K31/4433 , A61K31/47 , A61K31/505
CPC classification number: C07D319/18 , A61K31/165 , A61K31/277 , A61K31/357 , A61K31/40 , A61K31/4015 , A61K31/416 , A61K31/4178 , A61K31/4245 , A61K31/427 , A61K31/4433 , A61K31/453 , A61K31/4545 , A61K31/47 , A61K31/472 , A61K31/496 , A61K31/505 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C233/36 , C07C235/42 , C07C255/13 , C07C255/54 , C07C271/28 , C07C317/22 , C07D207/26 , C07D207/335 , C07D213/30 , C07D215/14 , C07D215/18 , C07D217/16 , C07D231/56 , C07D239/26 , C07D261/08 , C07D271/06 , C07D405/04 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , Y02A50/463 , A61K2300/00
Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
-
Patent Agency Ranking
公开(公告)号：US20150291549A1
公开(公告)日：2015-10-15
申请号：US14681772
申请日：2015-04-08
Applicant: Bristol-Myers Squibb Company
Inventor： Louis S. Chupak , Min Ding , Scott W. Martin , Xiaofan Zheng , Piyasena Hewawasam , Timothy P. Connolly , Ningning Xu , Kap-Sun Yeung , Juliang Zhu , David R. Langley , Daniel J. Tenney , Paul Michael Scola
IPC: C07D319/18 , C07D405/12 , A61K31/453 , C07D405/14 , A61K31/4545 , A61K45/06 , A61K31/472 , C07D413/12 , A61K31/5377 , C07D417/12 , A61K31/541 , A61K31/496 , A61K31/357 , C07D217/16
CPC classification number: C07D319/18 , A61K31/165 , A61K31/277 , A61K31/357 , A61K31/40 , A61K31/4015 , A61K31/416 , A61K31/4178 , A61K31/4245 , A61K31/427 , A61K31/4433 , A61K31/453 , A61K31/4545 , A61K31/47 , A61K31/472 , A61K31/496 , A61K31/505 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C233/36 , C07C235/42 , C07C255/13 , C07C255/54 , C07C271/28 , C07C317/22 , C07D207/26 , C07D207/335 , C07D213/30 , C07D215/14 , C07D215/18 , C07D217/16 , C07D231/56 , C07D239/26 , C07D261/08 , C07D271/06 , C07D405/04 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , Y02A50/463 , A61K2300/00
Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
Abstract translation: 本公开一般涉及可用作免疫调节剂的化合物。 本文提供的化合物，包含这些化合物的组合物及其使用方法。 本公开还涉及包含至少一种根据本公开的化合物的药物组合物，其可用于治疗各种疾病，包括癌症和感染性疾病。
-
7.发明申请公开(公告)号：US20150315218A1
公开(公告)日：2015-11-05
申请号：US14800315
申请日：2015-07-15
Applicant: Bristol-Myers Squibb Company
Inventor： Yasutsugu Ueda , Timothy P. Connolly , John F. Kadow , Nicholas A. Meanwell , Tao Wang , Chung-Pin H. Chen , Kap-Sun Yeung , Zhongxing Zhang , David Kenneth Leahy , Shawn K. Pack , Nachimuthu Soundararajan , Pierre Sirard , Kathia Levesque , Dominique Thoraval
IPC: C07F9/6561
CPC classification number: A61K31/675 , A61K31/497 , A61K31/519 , A61K45/06 , C07C215/10 , C07D471/04 , C07F9/062 , C07F9/5728 , C07F9/65515 , C07F9/65586 , C07F9/6561
Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection: wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
Abstract translation: 本发明提供前药化合物I，其药物组合物及其在治疗HIV感染中的用途：其中：X为C或N，条件是当X为N时，不存在R1; W为C或N，条件是当W为N时，R2不存在; V是C; E是氢或其药学上可接受的盐; 并且Y选自其中：L和M独立地选自C1-C6烷基，苯基，苄基，三烷基甲硅烷基，-2,2,2-三氯乙氧基和2-三甲基甲硅烷基乙氧基。
-
公开(公告)号：US20130253196A1
公开(公告)日：2013-09-26
申请号：US13861804
申请日：2013-04-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Yasutsugu Ueda , Timothy P. Connolly , John F. Kadow , Nicholas A. Meanwell , Tao Wang , Chung-Pin H. Chen , Kap-Sun Yeung , Zhongxing Zhang , David Kenneth Leahy , Shawn K. Pack , Nachimuthu Soundararajan , Pierre Sirard , Kathia Levesque , Dominique Thoraval
IPC: C07F9/6561
CPC classification number: A61K31/675 , A61K31/497 , A61K45/06 , C07D471/04 , C07F9/062 , C07F9/5728 , C07F9/65515 , C07F9/65586 , C07F9/6561
Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
-
公开(公告)号：US10745382B2
公开(公告)日：2020-08-18
申请号：US15290167
申请日：2016-10-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Kap-Sun Yeung , Timothy P. Connolly , David B. Frennesson , Katharine A. Grant-Young , Piyasena Hewawasam , David R. Langley , Zhaoxing Meng , Eric Mull , Kyle E. Parcella , Mark George Saulnier , Li-Qiang Sun , Alan Xiangdong Wang , Ningning Xu , Juliang Zhu , Paul Michael Scola
IPC: C07D401/14 , C07D213/71 , C07D455/02 , A61K31/135 , A61K31/138 , A61K31/166 , A61K31/397 , A61K31/40 , A61K31/4025 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/4453 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5375 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C215/20 , C07C235/46 , C07D205/04 , C07D207/12 , C07D207/14 , C07D207/16 , C07D211/22 , C07D213/80 , C07D213/82 , C07D213/85 , C07D265/30 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/08 , C07D491/08
Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
-
10.发明申请公开(公告)号：US20150232414A1
公开(公告)日：2015-08-20
申请号：US14704183
申请日：2015-05-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： YASUTSUGU UEDA , Timothy P. Connolly , John F. Kadow , Nicholas A. Meanwell , Tao Wang , Chung-Pin H. Chen , Kap-Sun Yeung , Zhongxing Zhang , David Kenneth Leahy , Shawn K. Pack , Nachimuthu Soundararajan , Pierre Sirard , Kathia Levesque , Dominique Thoraval
IPC: C07C215/10 , C07D471/04
CPC classification number: A61K31/675 , A61K31/497 , A61K31/519 , A61K45/06 , C07C215/10 , C07D471/04 , C07F9/062 , C07F9/5728 , C07F9/65515 , C07F9/65586 , C07F9/6561
Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
Abstract translation: 本发明提供前药化合物I，其药物组合物及其在治疗HIV感染中的用途。 其中：X为C或N，条件是当X为N时，R1不存在; W为C或N，条件是当W为N时，R2不存在; V是C; E是氢或其药学上可接受的盐; 并且Y选自本发明另外，本发明提供了可用于制备前药化合物I的中间体化合物II。其中：L和M独立地选自C 1 -C 6烷基，苯基，苄基，三烷基甲硅烷基， 2,2,2-三氯乙氧基和2-三甲基甲硅烷基乙氧基。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.039 seconds)
